Two Billion Novel Polio Vaccines Administred

According to the Global Polio Eradication Initiative (GPEI), 2 billion doses of the novel oral polio vaccine type 2 (nOPV2) have now been administered to children around the world, primarily in Africa.

Since the WHO approved its use in 2020, the nOPV2 vaccine has been an essential part of intensified efforts to curb outbreaks of circulating type 2 variant poliovirus (cVDPV2) in 35 countries. It has been 'triple-locked' through genetic engineering to prevent it from becoming harmful or producing mutations, says the GPEI.

The U.S. CDC Advisory Committee on Immunization Practices presentations on February 28, 2024, included an Introduction and Considerations for the Potential Use of nOPV2 as an Outbreak Control Measure in the U.S. 

The CDC currently publishes a Level 2 Travel Health Notice regarding the risk of polio in 39 countries.

As of November 10, 2025, the IPV polio vaccine is offered in the United States, and booster doses are recommended for specific international travelers.